Printer Friendly

Zimmer Biomet wins first FDA approval for the Tether for treating scoliosis in pediatrics.

M2 PHARMA-August 19, 2019-Zimmer Biomet wins first FDA approval for the Tether for treating scoliosis in pediatrics

(C)2019 M2 COMMUNICATIONS

Healthcare company Zimmer Biomet Holdings Inc (NYSE:ZBH) (SIX:ZBH) revealed on Friday the receipt of approval from the US Food and Drug Administration approval for The Tether for the fusion-less alternative surgery in young patients with scoliosis requiring surgery.

According to the company, the current surgical treatment for scoliosis is an invasive operation involving large incisions, extensive soft tissue disruption and restriction of spinal motion with metal rods inserted along both sides of the spine to secure and align the vertebrae.

The Tether, the company's anterior vertebral body tethering (AVBT) solution, uses a strong, flexible cord, rather than metal rods, to pull on the outside of a scoliosis curve to initially straighten the spine, while the inside of the curve is left free to grow. Additionally, unlike fusion metallic rods, The Tether is positioned utilizing an endoscopic minimally invasive approach through a few small openings between the ribs.

In conjunction, The Tether is available through the US FDA's humanitarian device exemption (HDE) pathway.

Under a collaboration with the US FDA and the Harms Study Group, a worldwide cohort of surgeons, the company will launch and perform a comprehensive, multi-centre, prospective research studies focused on pediatric spinal deformity.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 19, 2019
Words:230
Previous Article:AbbVie passes US FDA approval for RINVOQ for treating moderate to severe Rheumatoid Arthritis (RA).
Next Article:Edwards wins FDA approval for SAPIEN 3 TAVR for low-risk patients with severe, symptomatic aortic stenosis.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |